Mass vaccination of dogs is a mainstay for efforts to control rabies and other viral pathogens. The success of such programs is a function of the ability to vaccinate sufficient proportions of animals to develop herd immunity. However, fully assessing success in reaching target vaccination-levels and in understanding the outcome of mass vaccination efforts is hindered if insufficient information is available on the demographics of dog populations and the prevalence of the targeted pathogens. While such information can sometimes be gained from questionnaire surveys, greater precision requires direct assessment of the dog populations. Here we show how such information can be gained from surveys of dogs conducted in association with mass-vaccination programs. We conducted surveys of dogs in six villages in rural Maharashtra, India, between February and July 2011 as part of an effort to reduce the risk of human rabies and virus transmission from dogs to wildlife. Mass vaccination efforts were conducted in each village, and paired with blood sample collection and photographic mark-recapture approaches to gain epidemiologic and demographic data. This data in turn facilitated estimates of dog abundance, population density and structure, vaccination coverage, and seroprevalence of antibodies against canine adenovirus (CAV), canine parvovirus (CPV), and canine distemper virus (CDV). The median dog population size for the six villages was 134 (range 90-188), the median dog population density was 719 dogs per km(2) (range 526-969), and the median human:dog ratio for these six villages was 34 (range 30-47). The median household:dog ratio for the six villages was 6 (range 5-8). Following vaccination efforts, the median vaccination coverage achieved was 34% (range 24-42%). The dog populations consisted mostly of adult dogs (67-86%) and the median sex ratio for the study area was male biased (1.55 males per female; range 0.9-2.5). The seroprevalence of antibodies against CAV, CPV and CDV was 68, 88 and 73%, respectively. Mass vaccination campaigns provide an opportunity to obtain vital epidemiological and demographic data, and develop a clearer understanding of the threats and impacts of diseases and disease control measures.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.prevetmed.2013.04.003 | DOI Listing |
Vaccine
January 2025
Saw Swee Hock School of Public Health, National University of Singapore, and National University Health System, Singapore. Electronic address:
Background: Zika virus (ZIKV) continues to circulate in Southeast Asia following the 2015-2016 global epidemic, posing an ongoing risk of importation and disease spread for Singapore, a tropical city-state in the region. The virus remains a threat to pregnant women and their fetuses due to the risk of Congenital Zika Syndrome (CZS). Vaccines currently in development offer hope for reducing ZIKV infections and CZS cases.
View Article and Find Full Text PDFMicrob Biotechnol
January 2025
Izmir Biomedicine and Genome Center, Izmir, Turkey.
Low-cost and safe vaccines are needed to fill the vaccine inequity gap for future pandemics. Pichia pastoris is an ideal expression system for recombinant protein production due to its cost-effective and easy-to-scale-up process. Here, we developed a next-generation SARS-CoV2 Omicron BA.
View Article and Find Full Text PDFJ Med Virol
January 2025
Department of Laboratory Medicine, Ziekenhuis aan de Stroom, Antwerp, Belgium.
Three hospitals implemented molecular point-of-care tests (POCTs) to screen patients for SARS-CoV-2 infection upon admission during the 2021/2022 influenza season, which in Belgium lasted from January to April 2022. The samples were simultaneously tested for influenza A/B. Influenza positivity at admission was examined in relation to patient characteristics and symptomatology.
View Article and Find Full Text PDFVaccine
January 2025
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:
The mpox virus (MPXV) came to global attention with the 2022 global outbreak. Current vaccination and post-exposure prophylaxis against MPXV consists of live vaccinia whole virus-based vaccines including ACAM2000®, JYNNEOS™, and LC16m8 originally developed against smallpox. Here, we analyzed 152 vaccinia-derived peptides we identified by mass spectrometry for homology with MPXV-1 and MPXV-2 sequences to evaluate their potential relevance to MPXV-specific immunity.
View Article and Find Full Text PDFBMJ Open
December 2024
Department of Pediatrics, Khon Kaen University Faculty of Medicine, Khon Kaen, Thailand.
Objective: Infants are at a high risk of developing anaemia, which can arise from various causes, including inappropriate feeding practices. However, few infants attend anaemia screening programmes due to poor cooperation and being time-consuming. This study evaluated the accuracy of noninvasive total haemoglobin (Hb) spot-check monitoring as part of anaemia screening in healthy infants, compared with the conventional laboratory method.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!